4-(4-(1-(hex-5-ynyl)piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic acid

ID: ALA4212441

Chembl Id: CHEMBL4212441

PubChem CID: 139392057

Max Phase: Preclinical

Molecular Formula: C35H32F3NO2

Molecular Weight: 555.64

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C#CCCCCN1CCC(c2ccc(-c3cc(C(=O)O)cc4cc(-c5ccc(C(F)(F)F)cc5)ccc34)cc2)CC1

Standard InChI:  InChI=1S/C35H32F3NO2/c1-2-3-4-5-18-39-19-16-26(17-20-39)24-6-8-27(9-7-24)33-23-30(34(40)41)22-29-21-28(12-15-32(29)33)25-10-13-31(14-11-25)35(36,37)38/h1,6-15,21-23,26H,3-5,16-20H2,(H,40,41)

Standard InChI Key:  XNUCWDPJVQRZKC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4212441

    ---

Associated Targets(Human)

P2RY14 Tchem Purinergic receptor P2Y14 (692 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P2ry14 P2Y purinoceptor 14 (107 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 555.64Molecular Weight (Monoisotopic): 555.2385AlogP: 8.87#Rotatable Bonds: 8
Polar Surface Area: 40.54Molecular Species: ZWITTERIONHBA: 2HBD: 1
#RO5 Violations: 2HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.91CX Basic pKa: 9.75CX LogP: 5.96CX LogD: 5.95
Aromatic Rings: 4Heavy Atoms: 41QED Weighted: 0.17Np Likeness Score: -0.48

References

1. Yu J, Ciancetta A, Dudas S, Duca S, Lottermoser J, Jacobson KA..  (2018)  Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.,  61  (11): [PMID:29767967] [10.1021/acs.jmedchem.8b00168]
2. Mufti F, Jung YH, Giancotti LA, Yu J, Chen Z, Phung NB, Jacobson KA, Salvemini D..  (2020)  P2Y14 Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model.,  11  (6): [PMID:32551012] [10.1021/acsmedchemlett.0c00115]
3. Jung YH, Yu J, Wen Z, Salmaso V, Karcz TP, Phung NB, Chen Z, Duca S, Bennett JM, Dudas S, Salvemini D, Gao ZG, Cook DN, Jacobson KA..  (2020)  Exploration of Alternative Scaffolds for P2Y14 Receptor Antagonists Containing a Biaryl Core.,  63  (17): [PMID:32787142] [10.1021/acs.jmedchem.0c00745]

Source